Sleep Number Corp: Form 10-Q for the period ended Sep 28, 2024
Filed with the SEC on Nov 5, 2024 and accepted by EDGAR at Nov 5, 2024, 16:23 ET.
Management's discussion and analysis
As filed, 38,262 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide
a reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of
management on its financial condition, results of operations, liquidity and certain other factors that may affect the
Company’s future results. MD&A is presented in seven sections:
- Forward-Looking Statements and Risk Factors
- Business Overview
- Results of Operations
- Liquidity and Capital Resources
- Non-GAAP Data Reconciliations
- Off-Balance-Sheet Arrangements and Contractual Obligations
- Critical Accounting Policies
Forward-looking Statements and Risk Factors
The discussion in this Quarterly Report on Form 10-Q contains certain forward-looking statements that relate to
future plans, events, financial results or performance. You can identify forward-looking statements by those that
are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or
the negative of these or similar terms. These statements are subject to certain risks and uncertainties that could
cause actual results to differ materially from the Company’s historical experience and its present expectations or
projections. These risks and uncertainties include, among others:
- Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;
- Increases in interest rates, which have increased the cost of servicing the Company’s indebtedness;
- Availability of attractive and cost-effective consumer credit options;
- Ability to achieve savings and efficiencies from cost savings plans related to business restructuring actions and to
avoid unexpected adverse effects;
- Dependence on, and ability to maintain working relationships and favorable contractual terms with key suppliers and
third parties;
- Fluctuations in commodity costs or third-party delivery or logistics costs and other inflationary pressures;
- Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,
labor challenges, foreign currency fluctuations, inflation, and climate or other disasters, and resulting supply
shortages and production and delivery delays and disruptions;
- Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages, as well as
carrying excess levels of inventory for various products from time to time, which may leave the Company vulnerable
to inventory obsolescence and write-downs;
- The effectiveness of the Company’s marketing strategy and promotional efforts;
- The execution of the Company’s Total Retail distribution strategy;
- Ability to achieve and maintain high levels of product quality and to improve and expand the product line;
- Ability to protect the Company’s technology, trademarks, and brand and the adequacy of its intellectual property
rights;
- Ability to effectively compete;
- Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,
assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer
service operations;
- Ability to comply with existing and changing government regulations and laws;
- Pending or unforeseen litigation and the potential for associated adverse publicity;
- The adequacy of the Company’s and third-party information systems and costs and disruptions related to upgrading
or maintaining these systems;
16 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Index
- The Company’s ability to identify and withstand cyber threats that could compromise the security of its systems,
result in a data breach or business disruption;
- Risks associated with advancements in or adoption of artificial intelligence technologies;
- The Company’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and
effective personnel;
- The volatility of the Company’s stock, its removal from various stock indices, and the potential negative effects of
shareholder activism or of changes in coverage by securities analysts;
- Environmental, social and governance risks, including increasing regulation and stakeholder expectations; and
- The Company’s ability to adapt to climate change and readiness for legal or regulatory responses thereto.
Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk
Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent
Quarterly Reports on Form 10-Q.
The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this
Quarterly Report on Form 10-Q.
Business Overview
Sleep Number is a wellness technology company and market leader in the design, manufacturing, marketing and
distribution of innovative sleep solutions. The Company’s purpose is to improve the health and wellbeing of society
through higher quality sleep; to date, it has improved the lives of nearly 16 million people. Sleep Number’s Smart
Sleepers benefit from individualized sleep experiences, night after night, and are experiencing the physical, mental and
emotional benefits of life-changing sleep.
Sleep Number’s life-changing, differentiated smart beds combine physical and digital innovations, integrating
unparalleled physical comfort with a proprietary technology platform. The smart beds offer the Company’s signature
firmness adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep needs of each
individual; “sense and do” technology uses the sensed data to automatically adjust the smart bed to keep the sleeper
comfortable throughout the night. Active temperature balancing technology supports the ideal climate for both sleepers
and solves a prevalent sleep challenge. Additionally, the smart beds are an exceptional value, with personalized sleep
insights delivered daily, new features regularly added to all smart beds through over-the-air updates, at a range of good,
better and best price points. Sleep Number® smart beds provide unique features, benefits and comfort designed for
improved sleep health and wellness for both sleepers.
The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized sleep
wellness platform, an ecosystem of almost 3 million highly engaged Smart Sleepers, a vertically integrated operating
model, and a culture of individuality, with an ambitious vision to become one of the world’s most beloved brands. Sleep
Number’s exclusive distribution supports lifelong customer relationships – through digital and in-store touchpoints – to
provide an exceptional brand experience. The Company’s more than 29 billion hours of longitudinal sleep data enables
strategic collaborations with world-leading health and research institutions, including Mayo Clinic and American Cancer
Society. And Sleep Number’s 3,700 purpose-driven team members are dedicated to the Company’s mission of
improving lives by individualizing sleep experiences.
In the fourth quarter of 2023, Sleep Number began transforming its operating model for greater financial resilience
across a range of economic environments. These cost improvement actions are broad-based. The Company’s
transformation progress, combined with rigorous execution of their differentiated strategy, positions it - when market
growth returns - to capitalize on their innovation leadership, accelerate profitable growth, generate strong cash flow, and
deliver increased value for shareholders. The Company generates revenue by marketing and selling its innovative smart
beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch
points including Stores, Online, Phone, and Chat (Total Retail).
17 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Results of Operations
Quarterly and Year-to-Date Results
Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including
increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return
rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/
closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new
product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity
costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,
consumer sentiment and general economic conditions. The extent to which these external factors will impact the
Company’s business and its consolidated financial results will depend on future developments, which are highly
uncertain and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that
may be achieved for any future period.
Highlights
Financial highlights for the three months ended September 28, 2024 were as follows:
- Net sales for the three months ended September 28, 2024 of $427 million decreased 10% from $473 million for the
same period one year ago due to the ongoing weakness in the mattress industry and consumers continuing to
scrutinize their spending.
- The net sales change resulted from a 9% comparable sales decrease in Total Retail. For additional details, see the
components of total net sales change on page 19.
- Average sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a
trailing twelve-month basis for the period ended September 28, 2024 totaled $2.7 million, compared with $3.0
million for the same period last year.
- Operating income for the three months ended September 28, 2024 was $8 million, compared with $5 million in the
prior-year period. The $3 million increase in operating income was driven by a $15 million reduction in operating
expenses and a 3.4 ppt. increase in the gross profit rate, offset by lower net sales. Operating expenses for the three
months ended September 28, 2024 included $2 million of restructuring costs.
- Adjusted EBITDA for the three months ended September 28, 2024 was $28 million, compared to $25 million in the
prior-year period as ongoing gross margin improvements and cost reduction actions partially offset the year-over-
year net sales decline.
- Gross profit rate of 60.8% was 3.4 ppt. higher than the prior-year period. The increase was primarily due to year-
over-year product cost reductions through value engineering and ongoing supplier negotiations and favorable
product mix. See the gross profit discussion on page 20 for additional details.
- The $15 million year-over-year reduction in the Company’s operating expenses was due to lower sales and
marketing and research and development expenses, partly offset by $2 million of restructuring costs.
- Net loss for the three months ended September 28, 2024 was $3 million, compared with a net loss of $2 million for
the same period one year ago. Net loss per diluted share was $0.14, compared with a net loss per diluted share of
$0.10 for the comparable period one year ago.
- The Company’s adjusted return on invested capital (Adjusted ROIC) was 4.5% on a trailing twelve-month basis for
the period ended September 28, 2024, compared with 14.9% for the comparable period one year ago.
- The Company generated $51 million in cash from operating activities for the nine months ended September 28,
2024, compared with $32 million for the same period one year ago.
- Free cash flow provided $34 million for the nine months ended September 28, 2024, compared with using $16
million for the same period one year ago.
- As of September 28, 2024, the Company had $517 million of borrowings under its revolving credit facility.
18 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.
Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.
| Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 | |||||
|---|---|---|---|---|---|---|---|---|
| Net sales | $426.6 | 100.0% | $472.6 | 100.0% | $1,305.5 | 100.0% | $1,458.0 | 100.0% |
| Cost of sales | 167.1 | 39.2% | 201.5 | 42.6% | 528.3 | 40.5% | 612.3 | 42.0% |
| Gross profit | 259.5 | 60.8% | 271.1 | 57.4% | 777.2 | 59.5% | 845.6 | 58.0% |
| Operating expenses: | ||||||||
| Sales and marketing | 205.5 | 48.2% | 221.1 | 46.8% | 596.4 | 45.7% | 649.4 | 44.5% |
| General and administrative | 33.1 | 7.8% | 31.9 | 6.8% | 111.7 | 8.6% | 111.1 | 7.6% |
| Research and development | 10.6 | 2.5% | 12.6 | 2.7% | 34.6 | 2.7% | 42.5 | 2.9% |
| Restructuring costs | 2.0 | 0.5% | — | 0.0% | 14.4 | 1.1% | — | 0.0% |
| Total operating expenses | 251.1 | 58.9% | 265.7 | 56.2% | 757.1 | 58.0% | 803.1 | 55.1% |
| Operating income | 8.4 | 2.0% | 5.4 | 1.1% | 20.1 | 1.5% | 42.5 | 2.9% |
| Interest expense, net | 12.1 | 2.8% | 11.0 | 2.3% | 36.6 | 2.8% | 30.0 | 2.1% |
| (Loss) income before income taxes | (3.6) | (0.8%) | (5.6) | (1.2%) | (16.5) | (1.3%) | 12.5 | 0.9% |
| Income tax (benefit) expense | (0.5) | (0.1%) | (3.3) | (0.7%) | (0.9) | (0.1%) | 2.6 | 0.2% |
| Net (loss) income | $(3.1) | (0.7%) | $(2.3) | (0.5%) | $(15.7) | (1.2%) | $9.9 | 0.7% |
| Net (loss) income per share: | ||||||||
| Basic | $(0.14) | $(0.10) | $(0.69) | $0.44 | ||||
| Diluted | $(0.14) | $(0.10) | $(0.69) | $0.44 | ||||
| Weighted-average number of common shares: | ||||||||
| Basic | 22.6 | 22.5 | 22.6 | 22.4 | ||||
| Diluted | 22.6 | 22.5 | 22.6 | 22.6 |
The percentage of total net sales, by dollar volume, was as follows:
| Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 | |
|---|---|---|---|---|
| Retail stores | 87.8% | 86.6% | 87.9% | 87.1% |
| Online, phone, chat and other | 12.2% | 13.4% | 12.1% | 12.9% |
| Total Company | 100.0% | 100.0% | 100.0% | 100.0% |
19 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
The components of total net sales change, including comparable net sales changes, were as follows:
| Sales change rates: | Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 |
|---|---|---|---|---|
| Retail comparable-store sales (1) | (7%) | (14%) | (9%) | (11%) |
| Online, phone and chat | (18%) | (14%) | (17%) | (13%) |
| Total Retail comparable sales change (1) | (9%) | (14%) | (10%) | (11%) |
| Net opened/closed stores and other | (1%) | 1% | 0% | 1% |
| Total Company | (10%) | (13%) | (10%) | (10%) |
(1) Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned
within the same shopping center remain in the comparable-store base.
Other sales metrics were as follows:
| Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 | |
|---|---|---|---|---|
| Average sales per store (1) (in thousands) | $2,670 | $2,952 | ||
| Average sales per square foot (1) | $863 | $963 | ||
| Stores > $2 million in net sales (2) | 60% | 67% | ||
| Stores > $3 million in net sales (2) | 20% | 27% | ||
| Average revenue per smart bed unit (3) | $5,771 | $5,640 | $5,778 | $5,822 |
(1) Trailing-twelve months Total Retail comparable sales per store open at least one year.
(2) Trailing-twelve months for stores open at least one year (excludes online, phone and chat sales).
(3) Represents Total Retail net sales divided by Total Retail smart bed units.
The number of retail stores operating was as follows:
| Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 | |
|---|---|---|---|---|
| Beginning of period | 646 | 672 | 672 | 670 |
| Opened | 1 | 8 | 11 | 27 |
| Closed | (4) | (2) | (40) | (19) |
| End of period | 643 | 678 | 643 | 678 |
20 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Comparison of Three Months Ended September 28, 2024 with Three Months Ended September 30, 2023
Net sales
Net sales for the three months ended September 28, 2024 of $427 million decreased 10% from $473 million for the
same period one year ago due to the ongoing weakness in the mattress industry and consumers continuing to scrutinize
their spending.
The net sales change consisted primarily of an 9% comparable sales decrease in Total Retail.
The $46 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a
$27 million decrease in Retail comparable net sales; (ii) a $12 million decrease from online, phone and chat; and (iii) a $7
million decrease from net store closings and other. Total Retail smart bed unit sales decreased 12% compared with the
prior year. Total Retail average revenue per smart bed unit increased by 2% to $5,771, compared with $5,640 in the
prior-year period.
Gross profit
Gross profit of $260 million for the three months ended September 28, 2024 decreased by $12 million, or 4%, compared
with $271 million for the same period one year ago. The gross profit rate increased to 60.8% of net sales for the three
months ended September 28, 2024, compared with 57.4% for the prior-year comparable period.
The current-year gross profit rate increase of 3.4 ppt. was mainly due to: (i) year-over-year product cost reductions
through value engineering and ongoing supplier negotiations, increased the rate by 1.7 ppt; (ii) a favorable product mix,
increased the rate by 1.0 ppt; (iii) and efficiency gains in our home delivery and logistics operations, increased the rate by
0.7 ppt. In addition, the gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including
changes in warranty expenses, return and exchange costs, manufacturing and supply chain operations and performance-
based incentive compensation.
Sales and marketing expenses
Sales and marketing expenses for the three months ended September 28, 2024 were $205 million, or 48.2% of net sales,
compared with $221 million, or 46.8% of net sales, for the same period one year ago. The current-year sales and
marketing expenses rate increase of 1.4 ppt. was primarily due to the deleveraging impact of an 10% net sales decline
offset by a 7% decrease in expenses including a 4% lower media spend.
General and administrative expenses
General and administrative (G&A) expenses totaled $33 million, or 7.8% of net sales, for the three months ended
September 28, 2024, compared with $32 million, or 6.8% of net sales, in the prior-year period. The $1 million increase in
G&A expenses consisted mainly of: (i) a $1.9 million year-over-year increase in company-wide, performance-based
incentive compensation; offset by (ii) a $0.6 million decrease in employee compensation on lower headcount; and (iii) a
$0.2 million decrease in other miscellaneous expenses. The G&A expenses rate increased by 1.0 ppt. in the current-year
period, compared with the same period one year ago due to the items discussed above offset by the deleveraging
impact of lower net sales.
Research and development expenses
Research and development (R&D) expenses decreased to $11 million for the three months ended September 28, 2024,
compared with $13 million with the same period last year primarily due to lower headcount and outside services. While
the Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained
environment.
Interest expense, net
Interest expense, net increased to $12 million for the three months ended September 28, 2024, compared with $11
million for the same period one year ago. The $1 million increase was mainly driven by a higher weighted-average
interest rate compared with the same period one year ago.
21 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Restructuring Costs
In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate
gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs
incurred in 2023, the Company incurred an additional $2.0 million and $14.4 million of restructuring costs during the
three and nine months ended September 28, 2024, respectively. Charges incurred related to this initiative were
comprised of contract termination costs, severance and employee-related benefits, professional fees and other, and
asset impairment charges and are included in the restructuring costs line in the Company’s consolidated statement of
operations. The Company expects an additional $2 million to $3 million of restructuring costs to be incurred through the
remainder of 2024, primarily due to lease contract termination costs.
Income tax (benefit) expense
Income tax benefit totaled $0.5 million for the three months ended September 28, 2024, compared with income tax
benefit of $3 million for the same period last year. The change in income tax benefit was primarily due to the impact of
the loss before income tax levels.
Comparison of Nine Months Ended September 28, 2024 with Nine Months Ended September 30, 2023
Net sales
Net sales for the nine months ended September 28, 2024 decreased by $152 million, or 10%, to $1.3 billion, compared
with $1.5 billion for the same period one year ago due to the ongoing weakness in the mattress industry and consumers
continuing to scrutinize their spending.
The net sales decrease consisted primarily of an 10% comparable sales decrease in Total Retail. For additional details,
see the components of total net sales change on page 19.
The $152 million net sales decrease compared with the same period one year ago was comprised of the following: (i) an
$112 million decrease in Retail comparable net sales; (ii) a $31 million decrease in online, phone and other sales; and (iii)
a $9 million decrease resulting from net store closings. Total smart bed unit sales declined 10% compared with the same
period one year ago. Average revenue per smart bed unit in Total Retail decreased by 1% to $5,778, compared with
$5,822 in the prior-year period.
Gross profit
Gross profit of $777 million for the nine months ended September 28, 2024 decreased by $68 million, or 8%, compared
with $846 million for the same period one year ago. The gross profit rate increased to 59.5% of net sales for the nine
months ended September 28, 2024, compared to 58.0% in the prior-year comparable period.
The current-year gross profit rate increase of 1.5 ppt. was impacted by: (i) year-over-year product cost reductions
through value engineering and ongoing supplier negotiations, increased the rate by 1.1 ppt (ii) favorable pricing actions
taken over the last twelve months increased the rate by 1.0 ppt; (iii) efficiency gains in home delivery and logistics
operations, increased the rate by 0.7 ppt; partially offset by (iv) product mix of FlexFit smart adjustable bases, which
pressured the rate by 1.0 ppt; and (v) lower delivered smart bed volume deleveraged the rate by 0.2 ppt. In addition, the
gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including changes in warranty
expenses, manufacturing and supply chain operations and performance-based incentive compensation.
Sales and marketing expenses
Sales and marketing expenses for the nine months ended September 28, 2024 were $596 million, or 45.7% of net sales,
compared with $649 million, or 44.5% of net sales, for the same period one year ago. The current-year sales and
marketing expenses rate increase of 1.2 ppt. was primarily due to deleveraging impact of a 10% net sales decline offset
by a 8% decrease in expenses including 6% lower media spend.
22 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
General and administrative expenses
General and administrative (G&A) expenses totaled $112 million, or 8.6% of net sales, for the nine months
ended September 28, 2024, compared with $111 million, or 7.6% of net sales, in the prior-year period. The $1
million increase in G&A expenses consisted of: (i) a $2.6 million year-over-year increase in company-wide, performance-
based incentive compensation; (ii) a $0.8 million increase in technology investments; (iii) an increase in miscellaneous
other expenses of $3.1 million, which benefited during the same period one year ago from legal and insurance
settlements of $1.8 million; largely offset by (iv) a $4.4 million reduction in employee compensation on lower headcount;
and (v) a $1.1 million decrease in other occupancy expenses. The G&A expenses rate increased by 1.0 ppt. in the
current-year period, compared with the same period one year ago due to the deleveraging impact of the 10% net sales
decrease.
Research and development expenses
Research and development (R&D) expenses decreased by 19% to $35 million for the nine months ended September 28,
2024, compared with $43 million for the same period one year ago on lower outside services and headcount. While the
Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained
environment.
Interest expense, net
Interest expense, net increased to $37 million for the nine months ended September 28, 2024, compared with $30
million for the same period one year ago. The $7 million increase was mainly driven by a higher weighted-average
interest rate compared with the same period one year ago.
Restructuring Costs
In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate
gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs
incurred in 2023, the Company incurred $14.4 million of restructuring costs in the first nine months of 2024. Charges
incurred related to this initiative were comprised of contract termination costs, severance and employee-related benefits,
professional fees and other, and asset impairment charges and are included in the restructuring costs line in the
Company’s consolidated statement of operations. The Company expects an additional $2 million to $3 million of
restructuring costs to be incurred through the remainder of 2024, primarily due to lease contract termination costs.
Income tax (benefit) expense
Income tax benefit totaled $0.9 million for the nine months ended September 28, 2024, compared with income tax
expense of $3 million last year. The change in income tax expense was primarily due to the change in (loss) income
before income taxes levels and the impact of discrete tax expenses. Discrete tax expense, primarily stock-based
compensation tax shortfalls, was $2.6 million for the nine months ended September 28, 2024, compared to $1.1 million
for the same period last year.
Liquidity and Capital Resources
Managing liquidity and capital resources is an important part of the Company’s commitment to deliver superior
shareholder value over time.
The Company’s primary sources of liquidity are cash flows provided by operating activities and cash available under its
$680 million revolving credit facility, as amended. As of September 28, 2024, the Company does not have any off-
balance sheet financing other than its $7 million in outstanding letters of credit. The cash generated from ongoing
operations and cash available under the revolving credit facility are expected to be adequate to maintain operations,
and fund anticipated expansion, strategic initiatives and contractual obligations such as lease payments and capital
commitments for new retail stores for the foreseeable future.
Cash and cash equivalents totaled $1.6 million and $2.5 million at September 28, 2024 and December 30, 2023,
respectively. Significant changes in cash and cash equivalents during the nine months ended September 28, 2024
primarily consisted of $51 million of cash provided by operating activities, offset by a $31 million decrease in short-term
23 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
borrowings, $17 million of cash used to purchase property and equipment, and $3 million of cash used to issue notes
receivable.
The following table summarizes cash flows (in millions). Amounts may not add due to rounding differences:
| Total cash provided by (used in): | Nine Months Ended September 28, 2024 | September 30, 2023 |
|---|---|---|
| Operating activities | $50.8 | $31.8 |
| Investing activities | (20.0) | (49.3) |
| Financing activities | (31.8) | 16.6 |
| Net decrease in cash and cash equivalents | $(0.9) | $(0.9) |
Net cash provided by operating activities for the nine months ended September 28, 2024 was $51 million, compared
with $32 million for the nine months ended September 30, 2023. Significant components of the year-over-year change in
cash provided by operating activities included: (i) a $25 million fluctuation in inventory due to lower sales volumes and
operational improvements; (ii) a $22 million fluctuation in customer prepayments; and (iii) a $8 million fluctuation in
accrued compensation and benefits; partially offset by (iii) a $26 million decrease in net income for the nine months
ended September 28, 2024 compared with the nine months ended September 30, 2023; and (iv) a $9 million fluctuation
in other accruals and liabilities.
Net cash used in investing activities for the nine months ended September 28, 2024 was $20 million, compared with $49
million for the nine months ended September 30, 2023. Cash used to purchase property and equipment was $17 million
for the nine months ended September 28, 2024, compared with $48 million for the same period one year ago. In
addition, the Company issued $3 million of notes receivable during the nine months ended September 28, 2024.
Net cash used in financing activities was $32 million for the nine months ended September 28, 2024, compared with net
cash provided by financing activities of $17 million for the same period last year. Short-term borrowings decreased by
$31 million during the current-year period due to a $23 million decrease in borrowings under the revolving credit facility
to $517 million and a $8 million decrease in book overdrafts, which are included in the net change in short-term
borrowings. During the nine months ended September 28, 2024, the Company repurchased $1 million of its stock
compared with $4 million (based on settlement dates, in connection with the vesting of employee restricted stock
awards) during the same period one year ago. The Company made no share repurchases under its Board-approved
share repurchase program in either period.
In the second quarter of fiscal 2022, the Company suspended share repurchases under its Board-approved share
repurchase program. At September 28, 2024, there was $348 million remaining authorization under the Board-approved
$600 million share repurchase program. There is no expiration date governing the period over which the Company can
repurchase shares.
At September 28, 2024, the Company had $517 million of borrowings under its revolving credit facility, $7 million in
outstanding letters of credit and net liquidity available under the credit facility of $156 million. Total availability under its
revolving credit facility was $680 million, which amortizes by $2.5 million per quarter through December 2026. At
September 28, 2024, the Company’s leverage ratio as defined in the credit agreement was 4.2x versus the permissible
net leverage ratio of 5.0x, the weighted-average interest rate on borrowings under the credit facility was 8.2% and the
Company was in compliance with all financial covenants.
24 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Index
Non-GAAP Data Reconciliations
Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)
The Company defines earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net income
plus: income tax expense, interest expense, depreciation and amortization, stock-based compensation, restructuring
costs and asset impairments. Management believes Adjusted EBITDA is a useful indicator of its financial performance
and its ability to generate cash from operating activities. The Company’s definition of Adjusted EBITDA may not be
comparable to similarly titled definitions used by other companies. The table below reconciles Adjusted EBITDA, which
is a non-GAAP financial measure, to the comparable GAAP financial measure.
Adjusted EBITDA calculations are as follows (in thousands):
| Three Months Ended September 28, 2024 | September 30, 2023 | Trailing-Twelve Months Ended September 28, 2024 | September 30, 2023 | |
|---|---|---|---|---|
| Net (loss) income | $(3,136) | $(2,318) | $(40,857) | $4,471 |
| Income tax (benefit) expense | (489) | (3,253) | (7,966) | 1,346 |
| Interest expense | 12,057 | 10,958 | 49,313 | 37,641 |
| Depreciation and amortization | 15,859 | 18,200 | 67,335 | 72,338 |
| Stock-based compensation | 1,432 | 982 | 13,523 | 15,511 |
| Restructuring costs | 1,963 | — | 30,110 | — |
| Asset impairments | — | 292 | 198 | 491 |
| Adjusted EBITDA | $27,686 | $24,861 | $111,656 | $131,798 |
Free Cash Flow
The Company’s “free cash flow” data is considered a non-GAAP financial measure and is not in accordance with, or
preferable to, “net cash provided by operating activities,” or GAAP financial data. However, the Company is providing
this information as it believes it facilitates analysis for investors and financial analysts.
The following table summarizes free cash flow calculations (in thousands):
| Nine Months Ended September 28, 2024 | September 30, 2023 | Trailing-Twelve Months Ended September 28, 2024 | September 30, 2023 | |
|---|---|---|---|---|
| Net cash provided by (used in) operating activities | $50,824 | $31,816 | $9,980 | $(12,168) |
| Subtract: Purchases of property and equipment | 17,218 | 48,022 | 26,252 | 64,668 |
| Free cash flow | $33,606 | $(16,206) | $(16,272) | $(76,836) |
25 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Index
Non-GAAP Data Reconciliations (continued)
Return on Invested Capital (Adjusted ROIC)
Adjusted ROIC is a financial measure the Company uses to determine how efficiently it deploys its capital. It quantifies
the return the Company earns on its adjusted invested capital. Management believes Adjusted ROIC is also a useful
metric for investors and financial analysts. The Company computes Adjusted ROIC as outlined below. Its definition and
calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other
companies.
The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested
capital, which are non-GAAP financial measures, to the comparable GAAP financial measures (in thousands):
| Adjusted net operating profit after taxes (Adjusted NOPAT) | Trailing-Twelve Months Ended September 28, 2024 | September 30, 2023 |
|---|---|---|
| Operating income | $490 | $43,458 |
| Add: Operating lease expense (1) | 27,371 | 27,497 |
| Less: Income taxes (2) | (5,474) | (1,168) |
| Adjusted NOPAT | $22,387 | $69,787 |
| Average adjusted invested capital | ||
| Total deficit | $(448,784) | $(420,687) |
| Add: Long-term debt (3) | 516,761 | 488,338 |
| Add: Operating lease obligations (4) | 401,153 | 439,722 |
| Total adjusted invested capital at end of period | $469,130 | $507,373 |
| Average adjusted invested capital (5) | $502,494 | $469,782 |
| Adjusted return on invested capital (Adjusted ROIC) (6) | 4.5% | 14.9% |
(1) Represents the interest expense component of lease expense included in the Company’s financial statements under ASC 842, Leases.
(2) Reflects annual effective income tax rates, before discrete adjustments, of 19.6% and 1.6% for September 28, 2024 and September 30, 2023,
respectively.
(3) Long-term debt includes existing finance lease liabilities.
(4) Reflects operating lease liabilities included in the Company’s financial statements under ASC 842.
(5) Average adjusted invested capital represents the average of the last five fiscal quarters’ ending adjusted invested capital balances.
(6) Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.
Note - the Company’s adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable
to, GAAP financial data. However, the Company is providing this information as it believe it facilitates analysis of the Company's financial performance
by investors and financial analysts.
GAAP - generally accepted accounting principles in the U.S.
Critical Accounting Policies
The Company discusses its critical accounting policies and estimates in Management’s Discussion and Analysis of
Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the fiscal year ended
December 30, 2023. There were no significant changes in the Company’s critical accounting policies since the end of
fiscal 2023.
26 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Index
Market risk
As filed, 480 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to changes in market-based short-term interest rates that will impact net interest expense. If
overall interest rates were one percentage point higher than current rates, annual net income would decrease by
$4.2 million based on the $517 million of borrowings under the credit facility at September 28, 2024. The Company does
not manage the interest-rate volatility risk of borrowings under the credit facility through the use of derivative
instruments.
Controls and procedures
As filed, 1,671 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), that are
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under
the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is
accumulated and communicated to the Company’s management, including its principal executive officer and principal
financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure. The Company’s management, with the participation of its principal executive officer and principal financial
officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as
of the end of the period covered by this quarterly report. Based on this evaluation, its principal executive officer and
principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of the end
of the period covered by this quarterly report.
Changes in Internal Control
There were no changes in the Company’s internal control over financial reporting during the fiscal quarter ended
September 28, 2024, that have materially affected, or are reasonably likely to materially affect, the Company’s internal
control over financial reporting.
27 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Index
Risk factors
As filed, 1,065 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company’s business, financial condition and operating results are subject to a number of risks and uncertainties,
including both those that are specific to the Company’s business and others that affect all businesses operating in a
global environment. Investors should carefully consider the information in this report under the heading, Management’s
Discussion and Analysis of Financial Condition and Results of Operations, and also the information under the heading,
Risk Factors, in the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q. The risk factors discussed in the Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q
including this Quarterly Report on Form 10-Q do not identify all risks that the Company faces because its business
operations could also be affected by additional risk factors that are not presently known to the Company or that it
currently considers to be immaterial to its operations.
28 | 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION
Index
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-06-30 to 2024-09-28 | $426.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-12-31 to 2024-09-28 | $1.31bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-06-30 to 2024-09-28 | $167.1m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2023-12-31 to 2024-09-28 | $528.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-06-30 to 2024-09-28 | $259.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-12-31 to 2024-09-28 | $777.2m | us-gaap:GrossProfit |
| Research and development | 3 months2024-06-30 to 2024-09-28 | $10.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-12-31 to 2024-09-28 | $34.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-06-30 to 2024-09-28 | $8.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-12-31 to 2024-09-28 | $20.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-06-30 to 2024-09-28 | $12.1m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2023-12-31 to 2024-09-28 | $36.6m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-06-30 to 2024-09-28 | −$489.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-12-31 to 2024-09-28 | −$863.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-06-30 to 2024-09-28 | −$3.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-12-31 to 2024-09-28 | −$15.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-06-30 to 2024-09-28 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-12-31 to 2024-09-28 | −$0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-06-30 to 2024-09-28 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-12-31 to 2024-09-28 | −$0.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-06-30 to 2024-09-28 | 22,643,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-12-31 to 2024-09-28 | 22,588,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-12-31 to 2024-09-28 | $50.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-12-31 to 2024-09-28 | $17.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2023-12-31 to 2024-09-28 | $728.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-09-28 | $1.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-28 | $170.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-28 | $864.7m | us-gaap:Assets |
| Current liabilities | At period end2024-09-28 | $894.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-28 | $1.31bn | us-gaap:Liabilities |
| Current portion of debt | At period end2024-09-28 | $516.5m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2024-09-28 | −$448.8m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-09-28 | 22,371,000 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000827187-24-000091. Last ingested by Listed: Oct 24, 2026, 14:57 ET. Listed shows no prices and gives no investment advice.